Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.820
+0.060 (2.17%)
Nov 28, 2025, 4:00 PM EST - Market closed
Fortress Biotech Revenue
Fortress Biotech had revenue of $17.63M in the quarter ending September 30, 2025, with 20.52% growth. This brings the company's revenue in the last twelve months to $62.30M, down -23.56% year-over-year. In the year 2024, Fortress Biotech had annual revenue of $57.68M, down -31.76%.
Revenue (ttm)
$62.30M
Revenue Growth
-23.56%
P/S Ratio
1.19
Revenue / Employee
$616,861
Employees
101
Market Cap
87.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.68M | -26.84M | -31.76% |
| Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
| Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
| Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
| Dec 31, 2020 | 45.60M | 8.97M | 24.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FBIO News
- 14 days ago - Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 15 days ago - Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 22 days ago - Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - GlobeNewsWire
- 23 days ago - Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 - GlobeNewsWire
- 5 weeks ago - Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference - GlobeNewsWire
- 5 weeks ago - Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout - GlobeNewsWire
- 7 weeks ago - Journey Medical Corporation to Participate in October 2025 Investor Conferences - GlobeNewsWire